Steven Silver
Stock Analyst at Argus Research
(3.91)
# 1,877
Out of 4,835 analysts
26
Total ratings
83.3%
Success rate
22.4%
Average return
Main Sectors:
Stocks Rated by Steven Silver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVS CVS Health | Maintained: Buy | $104 → $114 | $94.91 | +20.11% | 5 | Aug 19, 2026 | |
| SPCX Space Exploration Technologies | Upgraded: Buy | $160 | $143.34 | +11.62% | 2 | Aug 6, 2026 | |
| DXCM DexCom | Maintained: Buy | $90 → $96 | $89.60 | +7.14% | 3 | Aug 3, 2026 | |
| BAX Baxter International | Maintained: Hold | n/a | $25.94 | - | 4 | May 8, 2026 | |
| CAH Cardinal Health | Maintained: Buy | $189 → $248 | $234.98 | +5.54% | 4 | May 5, 2026 | |
| ITGR Integer Holdings | Downgraded: Hold | n/a | $125.09 | - | 2 | Oct 24, 2025 | |
| TZOO Travelzoo | Reiterated: Buy | $19 | $7.00 | n/a | 1 | May 11, 2022 | |
| THC Tenet Healthcare | Downgraded: Hold | n/a | $270.21 | n/a | 1 | Jun 13, 2014 | |
| ALNY Alnylam Pharmaceuticals | Rated: Buy | n/a | $228.61 | n/a | 2 | Jan 27, 2014 | |
| GILD Gilead Sciences | Maintained: Buy | $94 | $143.44 | n/a | 1 | Dec 9, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $12.22 | n/a | 1 | Oct 22, 2010 |
CVS Health
Aug 19, 2026
Maintained: Buy
Price Target: $104 → $114
Current: $94.91
Upside: +20.11%
Space Exploration Technologies
Aug 6, 2026
Upgraded: Buy
Price Target: $160
Current: $143.34
Upside: +11.62%
DexCom
Aug 3, 2026
Maintained: Buy
Price Target: $90 → $96
Current: $89.60
Upside: +7.14%
Baxter International
May 8, 2026
Maintained: Hold
Price Target: n/a
Current: $25.94
Upside: -
Cardinal Health
May 5, 2026
Maintained: Buy
Price Target: $189 → $248
Current: $234.98
Upside: +5.54%
Integer Holdings
Oct 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $125.09
Upside: -
Travelzoo
May 11, 2022
Reiterated: Buy
Price Target: $19
Current: $7.00
Upside: n/a
Tenet Healthcare
Jun 13, 2014
Downgraded: Hold
Price Target: n/a
Current: $270.21
Upside: n/a
Alnylam Pharmaceuticals
Jan 27, 2014
Rated: Buy
Price Target: n/a
Current: $228.61
Upside: n/a
Gilead Sciences
Dec 9, 2013
Maintained: Buy
Price Target: $94
Current: $143.44
Upside: n/a
Oct 22, 2010
Maintained: Buy
Price Target: n/a
Current: $12.22
Upside: n/a